Serum biomarkers for liver fibrosis.

Liver fibrosis is a common pathway in most chronic liver diseases, characterized by excessive extracellular matrix accumulation. Without treatment, fibrosis will ultimately result in cirrhosis, portal hypertension, and even liver failure. It is considered that liver fibrosis is reversible while cirrhosis is not, making it significant to diagnose and evaluate liver fibrogenesis timely. As the gold standard, liver biopsy is imperfect due to its invasiveness and sampling error. Therefore, attempts at uncovering noninvasive tests have become a hot topic in liver fibrosis. Nowadays, as an important category of noninvasive tests, serum biomarkers, which are safer, convenient, repeatable, and more acceptable, are widely discussed and commonly used in clinical practice. Serum biomarkers of liver fibrosis can be divided into class I (direct) and classⅡ (indirect) markers. However, the diagnostic efficiency still varies among studies. This article summarizes the most established and newly discovered serum biomarkers for hepatic fibrogenesis.Copyright © 2022. Published by Elsevier B.V.

Citation

Zhiyang Chen, Yichen Ma, Jingyao Cai, Mei Sun, Ling Zeng, Fengxi Wu, Yiru Zhang, Min Hu. Serum biomarkers for liver fibrosis. Clinica chimica acta; international journal of clinical chemistry. 2022 Sep 26

PMID: 36174721

search → result